Site Search
Professionals 188 results
Capabilities 60 results
Industry
Winston has been a major player in the life sciences industry for decades. We represent market-leading clients across this broad sector, including companies involved in pharmaceuticals, biologics, biosimilars, biotechnology, and medical devices. Our attorneys are seasoned practitioners—many of whom have technical degrees in areas key to the life sciences sector, including biology, chemistry, pharmacy, and biomedical engineering—and bring a unique understanding of the industry and perspective to our representations.
Industry
Practice Area
Privacy: Regulated Personal Information (RPI)
Winston’s Regulated Personal Information (RPI) Practice offers seamlessly integrated counseling and litigation services to companies looking for practical and solution-oriented assistance navigating the compliance, regulatory, and private class action enforcement risks presented by the emerging patchwork of complex (and often conflicting) privacy laws in the United States and beyond.
Experience 150 results
Experience
|December 11, 2025
Winston Takes the Checkered Flag After “Massive Win” Settlement
Winston squared off in the W.D.N.C. against lawyers for NASCAR in an antitrust lawsuit brought on behalf of racing teams Front Row Motorsports Inc. and 23X1 Racing LLC—the team co-owned by Michael Jordan and driver Denny Hamlin—alleging monopolization of the market for premier stock car racing teams. On December 11, 2025, nine days into trial and the morning after the plaintiffs rested their case, the parties jointly announced a settlement. Jeffrey Kessler, Jeanifer Parsigian, and Danielle Williams were recognized by American Lawyer with its top “Litigator of the Week” honors on December 19, 2025, for this historic settlement.
Experience
|December 3, 2025
US Tiger Securities Announced IPO
Winston & Strawn LLP is serving as U.S. securities counsel to US Tiger Securities, Inc., a full-service broker/dealer, in connection with the $10,000,000 initial public offering of SMJ International Holdings Inc., a Singapore-based premium flooring specialist. The Company priced 2,500,000 Class A ordinary shares at US$4.00 per share. The Class A ordinary shares are expected to begin trading on the NYSE American under the ticker symbol “SMJF” on December 4, 2025.
Experience
|October 1, 2025
AA Mission Acquisition Corp. II - Initial Public Offering
Winston & Strawn LLP represented AA Mission Acquisition Corp. II, a blank check company, in the recent closing of its $100 million Initial Public Offering (IPO). The offering consisted of 10,000,000 units priced at $10.00 per unit, before deducting underwriting discounts and estimated offering expenses. The units began trading on the New York Stock Exchange (NYSE) under the ticker symbol “YCY.U” on October 1, 2025.
Insights & News 1,478 results
Global Trade & Foreign Policy Insights
|February 23, 2026
|10+ Min Read
Cari’s Legal Exchange: Navigating Evolving ICE Enforcement
In this episode of Cari’s Legal Exchange, Cari speaks with Damien Diggs, who shares practical insights on evolving ICE workplace enforcement, including how employers can prepare for inspections or raids, respond during enforcement actions, and what obligations and best practices apply after an inspection.
Benefits Blast
|February 17, 2026
|9 Min Read
Recent developments at the federal legislative and regulatory levels signal a significant shift toward greater transparency requirements in the pharmacy benefit management (PBM) industry.
In the Media
|February 12, 2026
|1 Min Read
Eva Davis Featured on Bloomberg TV’s Investment Committee
Winston & Strawn partner Eva Davis appeared on Bloomberg TV’s Investment Committee, a Bloomberg Deals segment that brings together industry leaders to discuss leading investment ideas and emerging deal opportunities. Eva joined Kroll Investment Banking Global Head Joshua Benn, and Bain & Company U.S. Consumer & Retail Investing Vertical Co-Head Emily Miller, for a discussion on where investors should consider deploying capital in the consumer sector.
Other Results 66 results
Law Glossary
Generic drugs are typically small, chemically synthesized molecules—that is, they have relatively low molecular weights, frequently less than 1000 daltons and usually between 300 and 700 daltons. Biosimilars, on the other hand, are typically substantially larger in molecular weight than small molecule drugs. For example, a monoclonal antibody—a typical biosimilar drug—generally has a molecular weight in excess of 150,000 daltons. In contrast, aspirin—a typical small molecule drug—has a molecular weight of 180 daltons.
Law Glossary
A biologic—or biologic product—is a medicine made from or by living cells, typically through a series of complex processing steps. The Public Health Service Act defines a “biological product” as “a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein (except any chemically synthesized polypeptide), or analogous product, or arsphenamine or derivative of arsphenamine (or another trivalent organic arsenic compound), applicable to the prevention, treatment, or cure of a disease or condition of human beings.” (42 U.S.C. § 262(i).)
Law Glossary
What Is a Qualified Retirement Plan?
A qualified retirement plan is a retirement plan established by an employer that is designed to provide retirement income to designated employees and their beneficiaries, which meets certain IRS Code requirements in terms of both form and operation. Common plan types are 401(k) plans, pension plans, and profit-sharing plans. A qualified retirement plan may allow for both employer and employee contributions. Employers must follow procedures to ensure participants and beneficiaries are able to receive their benefits. They must also stay apprised of changes in retirement plan laws and regulations. Qualified retirement plans provide certain tax advantages to employers and tax deferral advantages to employees who are contributing. Taxes on earnings from the contributions are also deferred until the employee withdraws them from the plan.